The Phase 3 DeLLphi-304 trial data presented at ASCO 2025 showed that Imdelltra® (tarlatamab-dlle) reduced the risk of death ...

Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

Investigators used the Shiny method, which employs artificial intelligence, to indirectly compare the efficacy of novel systemic therapies for urothelial cancer using phase 3 trial data.

Note that in applying relative entropy to model risk measurement we need not make this assumption but rather we are able to test whether this assumption is valid. We meet our previously stated ...